The relationship between clients' expected and actual treatment duration.

Psychotherapy ◽  
1986 ◽  
Vol 23 (4) ◽  
pp. 532-534 ◽  
Author(s):  
Gene Pekarik ◽  
Michael Wierzbicki
Keyword(s):  
Treatment Duration ◽  
Actual Treatment ◽  
The Relationship

scholarly journals Evaluation of Time to Resolution of Medical Necrotizing Enterocolitis Using Severity-Guided Management in a Neonatal Intensive Care Unit

2021 ◽  
Vol 26 (2) ◽  
pp. 179-186
Author(s):  
Katelyn E. Bull ◽  
Andrew B. Gainey ◽  
Christina L. Cox ◽  
Anna-Kathryn Burch ◽  
Martin Durkin ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Necrotizing Enterocolitis ◽  
Treatment Duration ◽  
Neonatal Intensive Care ◽  
Primary Outcome ◽  
Antimicrobial Treatment ◽  
Surrogate Markers ◽  
Antibiotic Duration ◽  
The Relationship

OBJECTIVE No studies, to our knowledge, have determined the relationship between symptom resolution and timing of antimicrobial discontinuation in necrotizing enterocolitis (NEC). Our study seeks to determine the period to NEC resolution by using severity-guided management, based on surrogate markers used in the diagnosis of NEC. METHODS This retrospective, observational review included patients in our NICU with NEC from June 1, 2012, to June 1, 2018. Patients were excluded for surgical NEC, a positive blood culture or transfer from an outside institution at the time of NEC, presence of a peritoneal drain, or death prior to NEC resolution. The primary outcome was time to resolution of NEC, measured by return to baseline of surrogate markers used in the diagnosis of NEC. RESULTS The median times to resolution in days, based on our institution's NEC severity group, were as follows: mild 3 (range, 1–4); moderate 4 (range, 1–17); severe 9 (range, 5–21). No difference in NEC recurrence was found based on antibiotic duration (OR 0.803; 95% CI, 0.142–4.225). CONCLUSIONS Time to resolution of NEC differs by severity group, suggesting a need for different treatment durations. Recurrence of NEC did not differ between groups, suggesting that shorter antibiotic durations do not lead to an increased incidence of NEC recurrence. Further exploration of the optimal antimicrobial treatment duration for NEC is warranted.

Major lab abnormalities as biomarkers in patients treated with immune checkpoint inhibitors: A single institution study of 1044 patients.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14108-e14108
Author(s):  
Kai Laukamp ◽  
Joseph Liput ◽  
Daniel Arnold Smith ◽  
Ariel Ann Nelson ◽  
Nikhil H. Ramaiya ◽  
...  
Keyword(s):  
Overall Survival ◽  
Immune Checkpoint ◽  
Scoring System ◽  
Treatment Duration ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Cancer Type ◽  
Chi Square ◽  
Male Patients ◽  
The Relationship

e14108 Background: Over the past decade, immune checkpoint inhibitors (ICI) have gained increased importance in modern cancer treatment. In this study we investigate the relationship between major lab abnormalities and ICI treatment duration. Methods: 1044 patients receiving ICIs between 2010-2018 were included in this retrospective study. The following parameters were analyzed: gender, age, race, cancer type, lab abnormalities for kidneys, pancreas, liver and thyroid, and treatment duration. Lab abnormalities were grouped and used in a scoring-system (0: no lab abnormalities, 1: one abnormal parameter, and 2: two or more abnormal parameters). For statistical analysis, Likelihood Ratio Chi-Square and Mann-Whitney U tests were applied. Results: The patient cohort included 386 female and 473 male patients with a mean age of 67.8±12.5 years. Primary cancer distribution included lung cancer (n = 439), melanoma (n = 253), head and neck cancer (n = 72), renal cancer (n = 53), lymphoma (n = 33), bladder cancer (n = 42), breast cancer (n = 28), and other malignancies (n = 124). Patients received one (n = 875) or a combination (n = 169) of ICIs for a mean of 152.2±215.8 days, with highest counts for nivolumab (n = 465), pembrolizumab (n = 275), ipilimumab (n = 95), and nivolumab & ipilimumab (n = 130) and others (n = 79). Patients with higher values in the scoring-system or more lab abnormalities had significantly longer treatment duration (Score 0: 107±170, 1: 159±199, 2: 244±282 days, p < 0.001). Furthermore, patients treated with ICI combination therapy demonstrated higher scores (1.1±0.8 vs. 0.5±0.7, p < 0.001) and longer treatment durations (236±304 vs. 127±175 days, p < 0.001). Patients with scores of ≥1 in the scoring system had improved overall survival (451±475 vs. 369±526 days, p < 0.001), and patients treated with two or more ICIs lived longer (563±524 vs. 377±496 days, p = 0.003). Therapy duration was also positively correlated with survival (Spearman’s rho correlation r = 0.64, p < 0.001). Conclusions: Our current exploratory study demonstrates associations between major lab abnormalities and both treatment duration and overall survival in patients treated with immune checkpoint inhibitors.

scholarly journals Investigation on the Relationship between Initial Dose and Treatment Duration of Lenalidomide for Multiple Myeloma

2017 ◽  
Vol 43 (10) ◽  
pp. 563-568
Author(s):  
Hiromu Tanigawa ◽  
Eiseki Usami ◽  
Michio Kimura ◽  
Tadashi Yano ◽  
Tomoaki Yoshimura ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Initial Dose ◽  
Treatment Duration ◽  
The Relationship

scholarly journals T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly

2016 ◽  
Vol 23 (11) ◽  
pp. 871-881 ◽  
Author(s):  
Iulia Potorac ◽  
Patrick Petrossians ◽  
Adrian F Daly ◽  
Orsalia Alexopoulou ◽  
Sophie Borot ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Signal Intensity ◽  
Treatment Duration ◽  
Large Population ◽  
Somatostatin Analogs ◽  
Subsequent Treatment ◽  
Tumor Shrinkage ◽  
Predictive Tool ◽  
Mri Sequences ◽  
The Relationship

GH-secreting pituitary adenomas can be hypo-, iso- or hyper-intense on T2-weighted MRI sequences. We conducted the current multicenter study in a large population of patients with acromegaly to analyze the relationship between T2-weighted signal intensity on diagnostic MRI and hormonal and tumoral responses to somatostatin analogs (SSA) as primary monotherapy. Acromegaly patients receiving primary SSA for at least 3 months were included in the study. Hormonal, clinical and general MRI assessments were performed and assessed centrally. We included 120 patients with acromegaly. At diagnosis, 84, 17 and 19 tumors were T2-hypo-, iso- and hyper-intense, respectively. SSA treatment duration, cumulative and mean monthly doses were similar in the three groups. Patients with T2-hypo-intense adenomas had median SSA-induced decreases in GH and IGF-1 of 88% and 59% respectively, which were significantly greater than the decreases observed in the T2-iso- and hyper-intense groups (P < 0.001). Tumor shrinkage on SSA was also significantly greater in the T2-hypo-intense group (38%) compared with the T2-iso- and hyper-intense groups (8% and 3%, respectively;P < 0.0001). The response to SSA correlated with the calculated T2 intensity: the lower the T2-weighted intensity, the greater the decrease in random GH (P < 0.0001,r = 0.22), IGF-1 (P < 0.0001,r = 0.14) and adenoma volume (P < 0.0001,r = 0.33). The T2-weighted signal intensity of GH-secreting adenomas at diagnosis correlates with hormone reduction and tumor shrinkage in response to primary SSA treatment in acromegaly. This study supports its use as a generally available predictive tool at diagnosis that could help to guide subsequent treatment choices in acromegaly.

scholarly journals Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0250147
Author(s):  
Diana Laila Ramatillah ◽  
Suri Isnaini
Keyword(s):  
Survival Rate ◽  
Clinical Outcome ◽  
Clinical Outcomes ◽  
Treatment Duration ◽  
Antiviral Agent ◽  
Duration Of Treatment ◽  
Kaplan Meier ◽  
Average Survival ◽  
The Relationship ◽  
Average Survival Rate

Background Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a virus that causes COVID-19, which has become a worldwide pandemic. However, until now, there is no vaccine or specific drug to prevent or treat COVID-19. Objectives To find out the effective treatment as an antiviral agent for COVID-19, to determine the correlation between sociodemography with clinical outcomes and duration of treatment, and to determine the relationship between comorbidities with clinical outcomes and duration of treatment for COVID-19 patients. Methods A prospective cohort study was conducted in this study. This study included only confirmed COVID-19 patients who were admitted to the hospital during April-May 2020. Convenience sampling was used to select 103 patients, but only 72 patients were suitable for inclusion. Results The survival analysis for COVID-19 patients using the Kaplan Meier method showed that patients receiving Oseltamivir + Hydroxychloroquine had an average survival rate of about 83% after undergoing treatment of about ten days. Gender (p = 0.450) and age (p = 0.226) did not have a significant correlation with the duration of treatment for COVID-19 patients. Gender (p = 0.174) and age (p = 0.065) also did not have a significant correlation with clinical outcome of COVID-19 patients. Comorbidities showed a significant correlation with duration of treatment (p = 0.002) and clinical outcome (p = 0.014) of COVID-19 patients. Conclusion The most effective antiviral agent in this study based on treatment duration was the combination of Oseltamivir + Hydroxychloroquine. The higher the patient’s average treatment duration is, the lower the average survival rate for COVID-19 patients.

Sign in / Sign up

Export Citation Format

Share Document